Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles

Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles

Abstract Background Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancers with a 5-year survival below 10%. Systemic delivery of chemotherapy drugs has severe side effects in patients with PDA and does not significantly improve overall survival rate. It is highly desirable to ad...

Full description

Bibliographic Details
Main Authors: Shu-ta Wu, Anthony J. Fowler, Corey B. Garmon, Adam B. Fessler, Joshua D. Ogle, Kajal R. Grover, Bailey C. Allen, Chandra D. Williams, Ru Zhou, Mahboubeh Yazdanifar, Craig A. Ogle, Pinku Mukherjee
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
PLGA
Nanoparticles
Mucin 1
Anti-MUC1 antibody
Targeted delivery
Paclitaxel
Online Access:http://link.springer.com/article/10.1186/s12885-018-4393-7

Internet

http://link.springer.com/article/10.1186/s12885-018-4393-7

Similar Items